Page last updated: 2024-11-08

5,6-dichlorobenzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,6-dichlorobenzimidazole: inhibits transcript elongation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID331775
CHEMBL ID303252
SCHEMBL ID352396
MeSH IDM0287498

Synonyms (45)

Synonym
nsc-63938
5,6-dichloro-1h-benzimidazole
NCI60_002831
NCIMECH_000265
6478-73-5
nsc-326397
NSC326397 ,
smr000429730
5,6-dichloro-1h-benzoimidazole
MLS000767399
MAYBRIDGE1_006289
NCIOPEN2_002664
5,6-dichlorobenzimidazole
CHEMBL303252 ,
HMS559F19
AKOS005070780
A834884
5,6-dichloro-1h-benzimidazole;5,6-dichloro-1h-benzo[d]imidazole
NCGC00246380-01
5,6-dichloro-1h-1,3-benzodiazole
nsc 326397
CCG-35358
bdbm50404895
HMS2792P12
5R-0829
5,6-dichloro-1h-benzo[d]imidazole
1h-benzimidazole, 5,6-dichloro-
AM20080958
FT-0620643
STL322711
SCHEMBL352396
MB00935
5,6-dichloro-benzimidazole
1h-benzimidazole,5,6-dichloro-2-(methylthio)-
W-203407
DTXSID40215090
5,6-dichloro-1h-1,3-benzimidazole
mfcd00211325
1h-benzimidazole,5,6-dichloro-
CS-W022274
D5146
EN300-1240476
PD011793
62J7FY37SD
benzimidazole, 5,6-dichloro-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency19.01150.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2B1Rattus norvegicus (Norway rat)IC50 (µMol)81.28317.40007.80008.2000AID38394
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID75268The compound was tested in vitro against the protozoa Giardia lamblia, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID210973Percentage viability reduction of Trichinella spiralis muscle larvae after 3 days of incubation2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID67529The compound was tested in vitro against the protozoa Entamoeba histolytica, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID642705Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and biological evaluation of benzo[d]imidazole derivatives as potential anti-cancer agents.
AID284279Antiamnesic activity against Entamoeba histolytica2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Molecular modeling of some 1H-benzimidazole derivatives with biological activity against Entamoeba histolytica: a comparative molecular field analysis study.
AID642704Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and biological evaluation of benzo[d]imidazole derivatives as potential anti-cancer agents.
AID38394Inhibitory potency to aminopyrine N-demethylase activity (P450) in hepatic microsomes from phenobarbitone-induced rats.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID24235Partition coefficient (logP)1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (8.70)18.7374
1990's1 (4.35)18.2507
2000's12 (52.17)29.6817
2010's7 (30.43)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]